arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

GERON CORP

GERN
$0.95 ▼ -0.12 (-11.63%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
38
Health
Weak
Bearish
auto_awesome

Analytical Summary

GERON CORP faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $633.3M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -19.9% ↗
FCF / Share $-0.17 ↗
Trailing P/E —
Price / Book 2.7x
FCF Yield —
Debt / Equity 0.53
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$596.00K
↓ -57.2% —
Net Income Profit after all expenses
$-83.50M
↑ +52.2% —
Operating Margin Operating profit as % of sales
-497.3%
↓ -32259.0% —
FCF / Share Free cash flow per share
$-0.17
↑ +50.9% —
Long-Term Debt Long-term obligations
$119.55M
↑ +0.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
20
Financial Health ↑
42
Cash Quality ↑
77

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters